PriceTargets.com logo

PepGen - PEPG Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.20
  • Forecasted Upside: 97.87%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$12.23 As of 03/31/2023 01:00 AM ET
▲ +0.35 (2.95%)

This chart shows the closing price for PEPG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PepGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEPG

Analyst Price Target is $24.20
▲ +97.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for PepGen in the last 3 months. The average price target is $24.20, with a high forecast of $33.00 and a low forecast of $16.00. The average price target represents a 97.87% upside from the last price of $12.23.

This chart shows the closing price for PEPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in PepGen.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2023WedbushBoost TargetOutperform$17.00 ➝ $22.00Low
3/24/2023HC WainwrightReiterated RatingBuy$26.00Low
12/21/2022HC WainwrightInitiated CoverageBuy$26.00Low
11/10/2022SVB LeerinkLower TargetOutperform$40.00 ➝ $33.00Low
5/31/2022WedbushInitiated CoverageOutperform$17.00High
5/31/2022Stifel NicolausInitiated CoverageBuy$24.00High
5/31/2022SVB LeerinkInitiated CoverageOutperform$40.00High
5/31/2022Bank of AmericaInitiated CoverageBuy$16.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2022
  • 6 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

PepGen logo
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $12.23
Low: $11.25
High: $13.11

50 Day Range

MA: $15.79
Low: $11.44
High: $17.70

52 Week Range

Now: $12.23
Low: $4.32
High: $20.00

Volume

216,628 shs

Average Volume

34,412 shs

Market Capitalization

$290.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of PepGen?

The following equities research analysts have issued research reports on PepGen in the last twelve months: Bank of America Co., HC Wainwright, Stifel Nicolaus, SVB Leerink LLC, and Wedbush.
View the latest analyst ratings for PEPG.

What is the current price target for PepGen?

5 Wall Street analysts have set twelve-month price targets for PepGen in the last year. Their average twelve-month price target is $24.20, suggesting a possible upside of 97.9%. SVB Leerink LLC has the highest price target set, predicting PEPG will reach $33.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $16.00 for PepGen in the next year.
View the latest price targets for PEPG.

What is the current consensus analyst rating for PepGen?

PepGen currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PEPG will outperform the market and that investors should add to their positions of PepGen.
View the latest ratings for PEPG.

What other companies compete with PepGen?

Other companies that are similar to PepGen include Atea Pharmaceuticals, Cara Therapeutics, Vaxxinity, Verrica Pharmaceuticals and Organogenesis. Learn More about companies similar to PepGen.

How do I contact PepGen's investor relations team?

The company's listed phone number is 781-797-0979 and its investor relations email address is [email protected] The official website for PepGen is www.pepgen.com. Learn More about contacing PepGen investor relations.